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Abstract
Background:  Adenylosuccinate synthase (ADSS) catalyzes the first committed step of AMP
synthesis. It was suggested that the blood-derived RNA of ADSS was down-regulated in
schizophrenia (SZ) and one of the eight putative biomarker genes to discriminate SZ from normal
controls. However, it remains unclear whether the reduction of ADSS RNA is due to the
polymorphisms of the gene or not.
Methods: We attempted to examine the association of ADSS gene with schizophrenia in a
Chinese population of 480 schizophrenics and 502 normal controls. Genotyping was performed by
the Sequenom platform.
Results: The 6 marker SNPs (rs3102460, rs3127459, rs3127460, rs3127465, rs3006001, and
rs3003211) were genotyped. The frequencies of alleles, genotypes, and haplotypes were tested
between cases and controls. There was no significant difference of genotypic, allelic, or haplotypic
distributions of the 6 SNPs between the two groups.
Conclusion: Our data did not support ADSS gene as a susceptibility gene for SZ in Chinese Han
population. Large sample size study is needed to validate or replicate our association study,
especially from other ethnic populations.
Background
Schizophrenia is a complex genetic disorder characterized
by profound disturbances of cognition, emotion and
social functioning. The median lifetime prevalence of SZ
is 0.7%–0.8% [1]. The public health importance of SZ is
clear. Numerous family, twin, and adoption studies
showed conclusively that the risk of schizophrenia was
increased among the relatives of affected individuals and
that it was the result largely of genes rather than shared
environment [2]. It's believed that the disease tends to run
in families, with an estimated heritability of 80–85% [3].
In the children and siblings of individuals with schizo-
phrenia, the increase in risk is approximately 10-fold.
Recent decades, many candidate genes have been impli-
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cated in the susceptibility of SZ with independent replica-
tive evidences from multiple populations [2,4,5].
Following the searching of genetic basis for the mecha-
nism of SZ, some lines of evidences have also emerged
from other kinds of biomarkers, such as level of gene
expression. Recent advances have facilitated the use of cir-
culating blood to conduct genomic analyses of human
disease [6,7]. Vawter et al. [8] identified nine genes that
were differentially expressed between SZ patients and con-
trols. Thereafter, by analyzing the blood-derived RNA
from 74 samples, linear and non-linear combinations of
eight putative biomarker genes (APOBEC3B, ADSS, ATM,
CLC, CTBP1, DIDO1, CXCL1, and S100A9) were able to
discriminate among schizophrenia, bipolar disorder, and
control samples [9], with an overall accuracy of 95%–
97%. None of these genes have yet been investigated for
their association or linkage disequilibrium with SZ.
Among them, ADSS is down-regulated in the SZ patients.
The de novo biosynthesis of AMP from IMP involves two
steps, with the first step catalyzed by ADSS followed by
adenylosuccinate lyase catalyzing the second step [10].
The gene encoding ADSS maps to 1cen-q12, the chromo-
somal loci previously linked to schizophrenia in meta-
analysis [11,12]. The sequence of ADSS gene is 44 kb in
length, with 13 extrons and 12 introns.
However, it is unknown whether the alteration in ADSS
expression is due to defect of the gene, or secondary to
other disease-related factors. In order to address this issue,
and to test the hypothesis that sequence variations of
ADSS gene influence the risk for the disease, we con-
ducted a case-control association study on 6 SNPs
(rs3102460, rs3127459, rs3127460, rs3127465,
rs3006001, and rs3003211) within the gene in a Chinese
Han Population.
Methods
Subjects
Subjects were 480 unrelated schizophrenics and 502
healthy controls. Cases (age: 41.8 ± 10.3) were recruited
from Hong Kong hospitals. All patients were interviewed
using the Structured Clinical Interview for DSM-IV (SCID)
and met the DSM-IV diagnostic criteria for schizophrenia.
Healthy controls (age: 41.9 ± 9.79) were recruited from
blood donors who were not screened for psychiatric dis-
eases. However, in Hong Kong an individual would be
ineligible for blood donation if he is under doctor's care,
taking medications, awaiting test results or suffering from
any serious illness. All subjects were Han Chinese. Periph-
eral blood sample were obtained from the subjects. All
participants provided written informed consent.
Genotyping
In view of information from dbSNP [13], according to the
location and the heterozygosity of SNP, we selected 6
SNPs from intron-11 (rs3102460), intron-6 (rs3127459),
intron-4 (rs3127460), intron-1 (rs3127465, rs3006001
and rs3003211) to check the allelic and haplotypic asso-
ciation of ADSS with SZ. The average estimated heterozy-
gosity of these SNPs is 0.37, and they span 36 Kb
nucleotides in the 44 Kb pairs of ADSS.
We employed a Sequenom platform (Sequenom MassAR-
RAY system, Sequenom, San Diego CA) for assay design
and genotyping. SNP sites were amplified by PCR in mul-
tiplex format in 384-microtiter plates by a pair of specifi-
cally designed forward and reverse PCR primers. The
length of the amplicons for SNP capture ranged from 60
to 120 base pairs (bp). Following genomic amplification
of the target regions, PCR products were treated with
shrimp alkaline phosphatase for 20 minutes at 37°C to
dephosphorylate any residual nucleotides and to prevent
their future incorporation and interference with the
primer extension assay. Extension primers, DNA polymer-
ase, and a cocktail mixture of deoxynucleotides (dNTPs)
and dideoxynucleotide triphosphates (ddNTPs) were
added to each mix. These were then followed by cycles of
homogeneous MassEXTEND™ (hME) reaction probed by
the extension primers for each SNP. The MassARRAY™
typer software version 3.1 was then used to read out the
extended mass and assign the genotype call. Quality con-
trol criteria included genotype call rate of >80%, less than
1 duplicate errors (5 duplicates in each 96 well-plate), and
significant Hardy-Weinberg disequilibrium.
Statistical analyses
Hardy-Weinberg equilibrium, genotype and allele fre-
quencies between cases and controls for ADSS markers
were tested using PLINK [14]. Linkage disequilibrium
(LD) between markers was tested by Haploview [15].
Haplotype analyses were performed using UNPHASED
[16] as well as SHEsis [17]. UNPHASED contains a suite
of programs for association analysis of haplotype data,
including COCAPHASE and QTPHASE. The most signifi-
cant p-value in the haplotype analysis was corrected for
multiple testing by running 1000 permutations of the
data by COCAPHASE. In each permutation, the 'case' and
'control' labels were randomly re-assigned among subjects
and the best p value were stored to provide an empirical
frequency distribution. The program employs the expecta-
tion-maximization (EM) algorithm to estimate haplo-
types with unknown phases. Individuals with missing
genotype information at one or more loci were excluded
from analyses by UNPHASED. Haplotypes with frequen-
cies <3% in the whole sample were considered be to be
rare and excluded.Behavioral and Brain Functions 2008, 4:39 http://www.behavioralandbrainfunctions.com/content/4/1/39
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Results
Genotype and allele distributions of SNPs
The allele  and genotype frequencies of 6 SNPs among 480
SZ patients and 502 healthy controls were shown in table
1. The genotypic distributions of these six polymorphisms
did not deviate significantly from Hardy-Weinberg Equi-
librium in both patients and controls (p > 0.05). There
was no significant difference in genotype or allele fre-
quencies between cases and controls.
Patterns of LD
The patterns of Pair-wise LD between neighbouring SNPs
were shown in figure 1. Fairly tight linkage disequilibrium
was observed in any pair of the SNPs and the six markers
were in strong LD.
Haplotypes of the six markers
As can be seen in table 2, there is no global or individual
significant difference for 6-marker haplotype in our sam-
ple. Individual haplotype tests were performed by evalu-
ating the difference in risk between a specific haplotype
and all others grouped together. Also, we obtained no sig-
nificant difference in haplotype frequencies for two-,
three-, four-, or five-marker analyses between patients and
controls (data not shown).
Discussion
Although genome-wide scan for linkage in multiply-
affected families with schizophrenia has consumed lots of
money and effort, no forms of schizophrenia following
Mendelian inheritance patterns have yet been discovered
[2]. Numerous evidences show that multiple genes of
small effect contribute to increasing liability to SZ, which
seems to have a cumulative effect, and putatively, thresh-
old effect. On the other hand, the study on schizophrenia
has confirmed the vital role of genes in its etiology, but
has not so far identified the relationship between
observed genetic risks and specific DNA variants, protein
alterations, or biological processes [18], nor was diagnos-
tic neuropathology, or even unequivocally replicated
associations with the same alleles or haplotype within
each gene identified [4].
Meta-analyses of SZ linkage studies have provided evi-
dence of susceptibility in chromosomes 2p, 5q, 3p, 11q,
6p, 1q, 22q, 8p, 20q, 22q, and 14p [2,12], some of which
are strong enough to withstand rigorous correction for
Table 1: Genotypic and allelic distributions of the ADSS SNPs in cases and controls
SNP Genotype frequency (%) p (df = 2) Allele frequency (%) p(df = 1) OR(95%CI) HW p
CC CT TT C T
Rs3102460 ca441 48(10.9) 176(39.9) 217(49.2) 0.442 272(30.8) 610(69.2) 0.344 1.1(0.9–1.35) 0.181
co443 37(8.4) 181(40.9) 225(50.8) 255(28.8) 631(71.2) 1
AA AT TT A T
Rs3127459 ca476 26(5.5) 170(35.7) 280(58.8) 0.425 222(23.3) 730(76.7) 0.212 0.88(0.71–1.08) 1
co499 36(7.2) 185(37.1) 278(55.7) 257(25.8) 741(74.2) 0.484
TT AT AA T A
rs3127460 ca477 12(2.5) 149(31.2) 316(66.2) 0.740 173(18.1) 781(81.9) 0.487 0.92(0.74–1.16) 0.353
co501 16(3.2) 162(32.3) 323(64.5) 194(19.4) 808(80.6) 0.477
CC CT TT C T
rs3127465 ca470 11(2.3) 144(30.6) 315(67.0) 0.673 166(17.7) 774(82.3) 0.551 0.93(0.74–1.18) 0.340
co489 16(3.3) 151(30.9) 322(65.8) 183(18.7) 795(81.3) 0.882
CC AC AA C A
rs3006001 ca475 12(2.5) 146(30.7) 317(66.7) 0.680 170(17.9) 780(82.1) 0.409 0.91(0.72–1.14) 0.434
co496 16(3.2) 160(32.3) 320(64.5) 192(19.4) 800(80.6) 0.565
GG AG AA G A
rs3003211 ca436 50(11.5) 171(39.2) 215(49.3) 0.668 271(31.1) 601(68.9) 0.401 1.09(0.89–1.34) 0.093
co453 44(9.7) 177(39.1) 232(51.2) 265(29.2) 641(70.8) 0.256
ca = case, co = control. HW = Hardy-WeinbergBehavioral and Brain Functions 2008, 4:39 http://www.behavioralandbrainfunctions.com/content/4/1/39
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whole genome analysis (e.g. 1q, 6p, 6q, 15q) [19].
Recently, many polymorphisms located in regions of
chromosome 1 were reported as susceptibility loci for SZ
[5,20], including risk markers in 1q44 [21] 1q43 [22],
both of which lie adjacent to ADSS.
Although whole genome linkage scan and functional
studies have implied several very promising positional
candidates, such as NRG1 [23], DTNBP1 [24], COMT [4],
DISC1 [25], DAOA [26,27], RGS4 [28] and so on
[5,23,28-31], there may be several genes that play subtle
or weak roles in the pathogenesis of SZ, making it difficult
to investigate by traditional approaches. To tackle this
problem, another approach to finding potential candidate
genes is using microarray technology to examine RNA of
a gene which shows differential expression between
patients and controls, by which ADSS gene was suggested
as one of candidates for SZ.
Functionally, the ADSS catalyzes the key step in the syn-
thesis of AMP, which influences the energy metabolism
through the purine nucleotide cycle (PNC) and the AMPK
(AMP-activated protein kinase) pathway [32]. The reac-
tion is as follows: IMP+L-aspartate+GTP ↔ adenylosucci-
nate+GDP+phosphate. Genetically, ADSS gene resides in
the susceptibility loci and the blood-derived RNA of ADSS
was among the eight genes with putatively differential
diagnostic power for SZ. Hereto, there is no genetic asso-
ciation study of ADSS with SZ, and the mechanism of
hypo-expression of ADSS is elusive, nevertheless, it sug-
gested that ADSS gene was possibly involved in the
genetic architecture of SZ, for genetic variation or poly-
morphisms can dominate gene expression as well as con-
fer disease risk to human beings.
Our study is an exploration study to seek the trait's genetic
basis following a clue from RNA alterations in SZ. How-
ever, the data did not display any statistically significant
difference for both the allelic and genotypic distribution
between cases and controls. Although haplotype analysis
is a powerful tool for identifying candidate genes for com-
plex disease, there was no positive finding in current
study. Therefore, our result does not support the associa-
tion of ADSS gene with SZ. It implies that down-regula-
tion of ADSS in patients may not result from the gene's
polymorphisms.
One common issue in the study of complex diseases is the
limited sample size, resulting in inadequate power to
detect association. With regard to our data, assuming the
frequency of risk allele in controls to be 0.5, our sample of
480 cases and 502 controls is able to detect an odds ratio
(OR) of 1.43 or above with 80% power [33]. It is possible
that false-negative results may arise from lack of power.
Another issue of researches in multifactor diseases is the
underlying high degree of genetic heterogeneity of per-
plexing phenotype. SZ is not simply defined by several
major genes but rather evolves from addition or potentia-
tion of a specific cluster of genes, which subsequently
determine the genetic vulnerability of an individual. Thus,
Graphical representation of LD patterns of the six SNPs in  the total sample Figure 1
Graphical representation of LD patterns of the six 
SNPs in the total sample. The graphic represents the 
pairwise calculation of r2 for each pair of SNPs at each gene. 
Squares represent r2 values. Values within boxes are the 
measures of r2 between pairs of markers in a scale from 0 to 
100. If there is no value, r2 = 1.
Table 2: Estimated 6-SNPs haplotype frequencies and association significance
Haplotype Case(freq) Control(freq) χ2 p OR (95%CI) Global p
TTATAA 372(46.2) 364.7(45.0) 0.119 0.731 1.035 (0.850–1.260) 0.339
CTATAG 243(30.1) 221.3(27.3) 1.388 0.239 1.139 (0.917–1.413)
TATCCA 140(17.4) 156(19.3) 1.087 0.297 0.874 (0.679–1.126)
TAATAA 45(5.6) 57(7.0) 1.523 0.217 0.776 (0.518–1.162)
Freq = frequency. Haplotypes were omitted if the estimated haplotype probability was less than 3%.Behavioral and Brain Functions 2008, 4:39 http://www.behavioralandbrainfunctions.com/content/4/1/39
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there are likely different genes or sets of genes associated
with schizophrenia disorders in different populations
[34]. It is necessary to validate or replicate our association
results using independent samples especially from other
ethnic populations.
It's been suggested that the promoter and 5' flanking
region of murine ADSS gene possessed regulatory ele-
ments that could influence its expression [35]. In addi-
tion, ADSS has several splicing variants. Therefore, the
examinations of SNPs within 5' flanking region and those
potentially affecting splicing may be valuable in further
study.
Conclusion
In conclusion, our data did not support ADSS gene as a
susceptibility gene for SZ in Chinese Han population. Fur-
ther study on genetic regulation, neural network, or epige-
netics will facilitate to elucidate the role of ADSS in SZ.
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